Texas · 81205

Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) in Texas

Texas Medicare Avg
$93.09
0% above national avg
National Medicare Avg
$93.06
All states combined
Billed Charge (TX)
$157.51
What providers submit
Est. Commercial (TX)
$214.11
National avg: $208.46
Est. Cash / Self-Pay (TX)
$113.13
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

119
Services in TX
2
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Texas

Provider Medicare Services
Genview Diagnosis Inc $93.09 81
Cabot Lab Llc $93.09 38

Texas Pricing in Context

In Texas, CPT code 81205 (Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide)) carries an average Medicare payment of $93.09 — 0% above the national benchmark of $93.06. 2 providers across the state submitted claims for this procedure in 2023, performing 119 total services. Individual payments in TX ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Texas is $157.51, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Texas sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Texas lands near $214.11, with self-pay cash prices typically around $113.13. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) cost in Texas?

The average Medicare payment for Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) in Texas is $93.09, which is 0% above the national average of $93.06. Providers in TX typically bill $157.51 for this procedure.

What does Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) cost with insurance in Texas?

With commercial insurance in Texas, Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) costs an estimated $214.11. Without insurance, the estimated cash price is $113.13. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) in Texas?

2 providers in Texas billed Medicare for Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) in 2023, performing 119 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) cheaper in Texas than the national average?

No — Gene Analysis (branched-Chain Keto Acid Dehydrogenase E1, Beta Polypeptide) costs 0% above the national average in Texas. The state average Medicare payment is $93.09 compared to $93.06 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial